Biotech · Private company · Hopkinton, MA, US
Newleos Therapeutics, Inc.
Track this companyFree. Adds Newleos Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- BasmisanilPhase 2 · Dup15Q SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- NTX-1472Phase 2 · Social Anxiety Disorder (SAD)ClinicalTrials.gov · fetched Nov 12, 2026
- NTX-2001Phase 1 · Alcohol Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase II Study of Basmisanil in Children and Adolescents With Dup15q SyndromePHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07846215 · fetched Nov 12, 2026
- Study of NTX-2001 on Alcohol Consumption in Alcohol Use DisorderPHASE1 · RECRUITING · started Mar 20, 2026ClinicalTrials.gov NCT07520292 · fetched Nov 12, 2026
- A Study of NTX-1472 in Social Anxiety DisorderPHASE2 · RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT07323784 · fetched Nov 12, 2026
NIH awards1
- NTX-2001, a trace amine-associated receptor 1 (TAAR1) partial agonist, for the treatment of Cocaine Use DisorderFiscal year 2026 · $3.1MNIH RePORTER 1UG3DA066264-01 · fetched Nov 12, 2026